lyrm5b Antibody

What is LYRM5 antibody and what protein does it target?

LYRM5 antibody specifically targets the LYR motif-containing protein 5, also known as ETFRF1 (Electron transfer flavoprotein regulatory factor 1). This protein functions as a regulator of the electron transfer flavoprotein by promoting flavin removal from the ETF holoenzyme (composed of ETFA and ETFB) . The antibody is typically available as a rabbit polyclonal antibody that recognizes human LYRM5/ETFRF1 protein . Understanding this target is essential for designing appropriate experimental controls and interpreting results in functional studies of mitochondrial electron transport chains.

What applications is LYRM5 antibody validated for in research settings?

Based on current validation data, LYRM5 antibody is suitable for multiple research applications including:

• Western blotting (WB) - demonstrated effective at 1/100 dilution

• Immunohistochemistry on paraffin-embedded tissues (IHC-P) - effective at 1/50 dilution with heat-mediated antigen retrieval using citrate buffer (pH 6)

• Immunocytochemistry/Immunofluorescence (ICC/IF) - validated at 2 μg/ml concentration

• Enzyme-linked immunosorbent assay (ELISA)

For optimal results, researchers should perform antibody titration experiments for their specific sample types and experimental conditions, as antibody performance can vary across different cellular contexts and fixation methods.

What is the predicted molecular weight of the LYRM5 protein detected by this antibody?

The predicted band size for LYRM5 protein in Western blot applications is approximately 11 kDa . Researchers should anticipate this molecular weight when interpreting their Western blot results. Variations in observed molecular weight may occur due to post-translational modifications, alternative splicing, or sample preparation conditions. When overexpressing LYRM5 with additional tags (such as myc-DDK), the apparent molecular weight will increase accordingly by the size of the tag (~3.1 kDa for myc-DDK tag) .

How should I design proper controls when using LYRM5 antibody in my experiments?

Designing appropriate controls is crucial for antibody-based experiments:

• Negative controls:

  • Vector-only transfected cell lysates (as demonstrated in Western blot applications)

  • Secondary antibody-only controls (omitting primary antibody)

  • Isotype controls using non-specific IgG from the same species

  • Tissues/cells known not to express LYRM5

• Positive controls:

  • LYRM5 overexpression systems (such as the HEK-293T overexpression system shown in validation data)

  • Tissues with known LYRM5 expression (such as human stomach tissue, where LYRM5 has been detected in the cytoplasm of glandular cells)

  • RH-30 cells (human bone marrow metastasis cell line) which demonstrate LYRM5 localization to the microtubule organizing center

• Validation approaches:

  • Antibody specificity can be further validated using siRNA knockdown or CRISPR-Cas9 knockout of LYRM5

  • Peptide competition assays using the immunizing peptide

What sample preparation methods optimize LYRM5 antibody performance in different applications?

Optimal sample preparation varies by application:

• For Western blotting:

  • Use standard cell lysis buffers containing protease inhibitors

  • Denature samples at 95°C for 5 minutes in reducing SDS sample buffer

  • Load appropriate protein amounts (typically 20-40 μg total protein)

  • Include molecular weight markers to confirm band size (expected at 11 kDa)

• For IHC-P:

  • Perform heat-mediated antigen retrieval with citrate buffer at pH 6.0

  • Use paraffin-embedded sections of 4-6 μm thickness

  • Block with appropriate blocking buffer (typically 5% normal serum)

  • Incubate with primary antibody at 1/50 dilution

• For ICC/IF:

  • Fix cells using 4% paraformaldehyde

  • Permeabilize with 0.1-0.5% Triton X-100

  • Block with appropriate blocking buffer

  • Incubate with LYRM5 antibody at 2 μg/ml concentration

  • Include nuclear counterstain (DAPI) and cytoskeletal markers for localization studies

How can I optimize antibody dilution for my specific experimental conditions?

Antibody titration is essential for optimal signal-to-noise ratio:

• Serial dilution approach:

  • Begin with the manufacturer's recommended dilution (e.g., 1/100 for WB, 1/50 for IHC-P)

  • Test 2-3 dilutions above and below the recommended concentration

  • Evaluate signal strength and background for each dilution

  • Select the dilution providing maximum specific signal with minimal background

• Sample-specific considerations:

  • Expression levels vary between tissues and cell types

  • Different fixation methods may affect epitope accessibility

  • Primary tissue samples may require different dilutions than cell lines

• Application-specific optimization:

  • Western blotting: 1/100 dilution is a validated starting point

  • IHC-P: 1/50 dilution with citrate buffer antigen retrieval

  • ICC/IF: 2 μg/ml has been validated in RH-30 cells

How can LYRM5 antibody be used to investigate mitochondrial electron transfer pathways?

LYRM5 functions as a regulator of electron transfer flavoprotein by promoting flavin removal from the ETF holoenzyme . Researchers can leverage LYRM5 antibody to:

• Co-immunoprecipitation studies:

  • Pull down LYRM5 to identify interacting proteins within the electron transfer pathway

  • Confirm interactions with ETFA and ETFB components

  • Discover novel binding partners in different cellular contexts

• Subcellular localization studies:

  • Use ICC/IF to examine LYRM5 co-localization with mitochondrial markers

  • Investigate changes in localization under different metabolic conditions

  • Analyze localization in disease models with mitochondrial dysfunction

• Functional analyses:

  • Combine with metabolic flux assays to correlate LYRM5 expression with electron transfer efficiency

  • Examine LYRM5 expression changes during cellular stress responses

  • Investigate post-translational modifications of LYRM5 that might regulate its activity

What approaches can I use to validate LYRM5 antibody specificity for my research?

Antibody validation is critical for research integrity:

• Genetic validation:

  • CRISPR-Cas9 knockout verification - compare signals between wild-type and LYRM5-knockout cells

  • siRNA knockdown - demonstrate signal reduction corresponding to protein reduction

  • Overexpression systems - confirm signal increase in cells with LYRM5 overexpression

• Analytical validation:

  • Mass spectrometry confirmation of immunoprecipitated proteins

  • Peptide competition assays using the immunizing peptide

  • Comparing results using multiple antibodies targeting different epitopes of LYRM5

• Orthogonal validation:

  • Correlate protein expression (antibody-based) with mRNA expression (qPCR)

  • Compare subcellular localization across multiple detection methods

  • Verify functional consequences of LYRM5 perturbation with biochemical assays

How can LYRM5 antibody be adapted for high-throughput screening applications?

For large-scale studies, LYRM5 antibody can be implemented in:

• Tissue microarray (TMA) analysis:

  • Optimize IHC-P protocols for high-throughput screening

  • Develop standardized scoring systems for LYRM5 expression levels

  • Analyze expression patterns across multiple tissue types or disease states

• Automated microscopy platforms:

  • Adapt ICC/IF protocols for robotic liquid handling systems

  • Develop image analysis algorithms for quantifying LYRM5 expression and localization

  • Implement multi-parameter analysis correlating LYRM5 with other markers

• Flow cytometry applications:

  • Optimize antibody conjugation with fluorophores for flow cytometry

  • Develop intracellular staining protocols for LYRM5 detection

  • Combine with mitochondrial function markers for multiparameter analysis

What are common issues when using LYRM5 antibody in Western blotting and how can they be resolved?

Researchers commonly encounter these challenges:

• Weak or absent signal:

  • Increase antibody concentration (try 1/50 instead of 1/100)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use enhanced chemiluminescence detection systems

  • Verify protein transfer efficiency with reversible staining

  • Check sample preparation for protease activity

• Multiple bands or non-specific binding:

  • Increase blocking time or blocking agent concentration

  • Optimize washing steps (increase number or duration)

  • Reduce antibody concentration

  • Try alternative blocking agents (milk vs. BSA)

  • Confirm sample integrity (avoid protein degradation)

• Unexpected band size:

  • Consider post-translational modifications altering molecular weight

  • Verify running conditions of SDS-PAGE

  • Check for alternative splice variants of LYRM5

  • Confirm specificity with knockout/knockdown controls

How should I interpret subcellular localization patterns of LYRM5 in immunostaining experiments?

LYRM5 has been observed in specific subcellular locations:

• Expected localization patterns:

  • Cytoplasmic localization in glandular cells of human stomach tissue

  • Microtubule organizing center localization in RH-30 cells

  • Potential mitochondrial localization given its function in electron transfer

• Interpretation guidelines:

  • Always compare with appropriate organelle markers

  • Consider co-localization analysis with mitochondrial markers

  • Quantify localization patterns across multiple cells and experiments

  • Assess changes in localization under different cellular conditions

• Validation approaches:

  • Confirm localization with fractionation studies and Western blotting

  • Use super-resolution microscopy for detailed localization analysis

  • Compare localization patterns using antibodies targeting different epitopes

How can I quantitatively analyze LYRM5 expression levels in IHC or ICC experiments?

Quantitative analysis requires standardized approaches:

• Intensity scoring methods:

  • Develop a scoring system (e.g., 0-3+) for staining intensity

  • Calculate H-scores (intensity × percentage of positive cells)

  • Use digital image analysis software for objective quantification

  • Implement machine learning algorithms for pattern recognition

• Normalization approaches:

  • Normalize to appropriate housekeeping proteins

  • Include reference standards on each slide/plate

  • Analyze multiple fields per sample for representative quantification

  • Compare relative expression across experimental conditions

• Statistical considerations:

  • Determine appropriate sample sizes for statistical power

  • Apply suitable statistical tests based on data distribution

  • Account for batch effects in multi-experiment analyses

  • Consider blinded scoring to eliminate observer bias

How can LYRM5 antibody be used in combination with advanced imaging techniques?

Integrating LYRM5 antibody with cutting-edge imaging approaches:

• Super-resolution microscopy:

  • Adapt ICC/IF protocols for techniques like STORM, PALM, or STED

  • Investigate nanoscale distribution of LYRM5 within mitochondria

  • Examine co-localization with ETFA and ETFB at nanometer resolution

• Live-cell imaging applications:

  • Develop cell-permeable antibody fragments or nanobodies

  • Combine with genetically encoded tags for correlative microscopy

  • Monitor dynamic changes in LYRM5 localization during metabolic shifts

• Volumetric imaging approaches:

  • Implement LYRM5 antibody in tissue clearing techniques

  • Develop whole-organ imaging protocols to map LYRM5 distribution

  • Combine with multiplex antibody labeling for comprehensive protein interaction mapping

How might LYRM5 antibody be utilized in the context of B cell research and affinity maturation studies?

Recent advances in B cell biology suggest potential applications:

• Antibody engineering applications:

  • Use affinity maturation principles to enhance LYRM5 antibody specificity

  • Apply CDR walking strategies to optimize binding characteristics

  • Implement computational antibody design approaches to improve developability

• Therapeutic antibody development considerations:

  • Apply lessons from recent B cell research to antibody optimization

  • Consider biophysical and chemical properties that affect antibody stability

  • Utilize natural immune system wisdom for antibody enhancement, similar to approaches used in recent HIV antibody studies

• Integration with CRISPR technologies:

  • Apply B cell gene editing approaches similar to those described for HIV antibodies

  • Develop humanized antibody models through chromosome engineering

  • Enhance antibody affinity through directed evolution in engineered B cells

What methodological considerations should be addressed when developing new LYRM5 antibody derivatives or conjugates?

For researchers developing modified LYRM5 antibodies:

• Conjugation strategies:

  • Consider site-specific conjugation methods to preserve binding regions

  • Evaluate different fluorophores for specific applications (FITC, HRP)

  • Assess linker chemistry effects on antibody function and stability

  • Validate conjugate performance compared to unconjugated antibody

• Format optimization:

  • Evaluate full-length antibody versus fragments (Fab, F(ab')2, scFv)

  • Consider recombinant expression versus chemical modification approaches

  • Test monoclonal derivatives for applications requiring higher specificity

  • Implement affinity maturation techniques to enhance binding properties

• Developability assessment:

  • Screen for sequences with liability issues (deamidation hotspots, unpaired cysteines)

  • Optimize for favorable physicochemical properties (solubility, stability)

  • Balance affinity improvement with other desirable properties

  • Apply computational prediction tools to identify potential issues before development

How do different applications of LYRM5 antibody compare in terms of sensitivity and specificity?

What are the comparative advantages of different antibody engineering approaches for LYRM5 study?

What experimental parameters should be systematically tested when optimizing LYRM5 antibody protocols?